» Articles » PMID: 29229429

Semi-mechanistic Pharmacokinetic-pharmacodynamic Modelling of Antibiotic Drug Combinations

Overview
Publisher Elsevier
Date 2017 Dec 13
PMID 29229429
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Deriving suitable dosing regimens for antibiotic combination therapy poses several challenges as the drug interaction can be highly complex, the traditional pharmacokinetic-pharmacodynamic (PKPD) index methodology cannot be applied straightforwardly, and exploring all possible dose combinations is unfeasible. Therefore, semi-mechanistic PKPD models developed based on in vitro single and combination experiments can be valuable to suggest suitable combination dosing regimens.

Aims: To outline how the interaction between two antibiotics has been characterized in semi-mechanistic PKPD models. We also explain how such models can be applied to support dosing regimens and design future studies.

Sources: PubMed search for published semi-mechanistic PKPD models of antibiotic drug combinations.

Content: Thirteen publications were identified where ten had applied subpopulation synergy to characterize the combined effect, i.e. independent killing rates for each drug and bacterial subpopulation. We report the various types of interaction functions that have been used to describe the combined drug effects and that characterized potential deviations from additivity under the PKPD model. Simulations from the models had commonly been performed to compare single versus combined dosing regimens and/or to propose improved dosing regimens.

Implications: Semi-mechanistic PKPD models allow for integration of knowledge on the interaction between antibiotics for various PK and PD profiles, and can account for associated variability within the population as well as parameter uncertainty. Decisions on suitable combination regimens can thereby be facilitated. We find the application of semi-mechanistic PKPD models to be essential for efficient development of antibiotic combination regimens that optimize bacterial killing and/or suppress resistance development.

Citing Articles

Stronger together: a cross-SIG perspective on improving drug development.

Fostvedt L, Zhou J, Kondic A, Androulakis I, Zhang T, Pryor M J Pharmacokinet Pharmacodyn. 2025; 52(1):14.

PMID: 39825146 DOI: 10.1007/s10928-024-09960-5.


Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus.

Saporta R, Nielsen E, Menetrey A, Cameron D, Nicolas-Metral V, Friberg L J Antimicrob Chemother. 2024; 79(12):3150-3159.

PMID: 39315768 PMC: 11638087. DOI: 10.1093/jac/dkae334.


Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model.

Zhao C, Kristoffersson A, Khan D, Lagerback P, Lustig U, Cao S Sci Rep. 2024; 14(1):11706.

PMID: 38778123 PMC: 11111785. DOI: 10.1038/s41598-024-61518-0.


Revisiting the Checkerboard to Inform Development of β-Lactam/β-Lactamase Inhibitor Combinations.

Bentley D Antibiotics (Basel). 2024; 13(4).

PMID: 38667012 PMC: 11047560. DOI: 10.3390/antibiotics13040337.


Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer's Perspective.

Bissantz C, Zampaloni C, David-Pierson P, Dieppois G, Guenther A, Trauner A Antibiotics (Basel). 2024; 13(1).

PMID: 38247631 PMC: 10812724. DOI: 10.3390/antibiotics13010072.